(Press-News.org) Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will present a variety of abstracts that aim to improve treatments for patients with lymphoma and acute leukemias at the 66th American Society of Hematology (ASH) Meeting & Exposition. The meeting is set to occur in San Diego, California, and virtually December 7 - 10, 2024.
Promising results from a phase 2 study (PrE0905) in patients with acute myeloid leukemia and new data from the practice-changing E1910 phase 3 trial are among the highlights. Results from the E1910 trial led to an FDA approval in June 2024 after it found that adding the immunotherapy drug blinatumomab to standard front-line consolidation chemotherapy keeps most patients with B-cell acute lymphoblastic leukemia in remission and improves their survival.
Details for the presentations are below, listed by type and date. Times are shown in Pacific Time.
New Data from the Practice-Changing E1910 Trial by ECOG-ACRIN
Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
Presenter: Nikolai A. Podoltsev, MD, PhD (Yale University)
Poster Abstract 4211 in Session 613
Date and Time: Monday, December 9, 2024, 6:00 - 8:00 PM
Location: San Diego Convention Center, Halls G-H
Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
Presenter: Michaela Liedtke, MD (Stanford University)
Oral Abstract 779 in Session 732
Date and Time: Monday, December 9, 10:30 AM - 12:00 PM
Presentation Time: 11:30 AM
Location: San Diego Convention Center, Room 6A
EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin
Presenter: Carolin S. Escherich, MD (St. Jude Children’s Research Hospital)
Oral Abstract 830 in Session 605
Date and Time: Monday, December 9, 2:45 - 4:15 PM
Presentation Time: 3:00 PM
Location: San Diego Convention Center, Ballroom 20 C-D
Trial Results
Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181
Presenter: Nina D. Wagner-Johnston, MD (Johns Hopkins University)
Oral Abstract 236 in Session 623
Date and Time: Saturday, December 7, 2:00 - 3:30 PM
Presentation Time: 2:15 PM
Location: Marriott Marquis San Diego Marina, Grand Ballroom 11-13
Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Pre0905 Study in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)
Presenter: Selina M. Luger, MD (University of Pennsylvania)
Oral Abstract 221 in Session 617
Date and Time: Saturday, December 7, 2:00 - 3:30 PM
Presentation Time: 3:00 PM
Location: Manchester Grand Hyatt San Diego, Seaport Ballrooms E-F-G-H
Other New Data from ECOG-ACRIN Trials
PKCδ-Mediated Phosphorylation of CD25 Initiates Feedback Control of Oncogenic Tyrosine Kinases in Acute Lymphoblastic Leukemia
Presenter: Ruifeng Sun, BS (Yale University)
Oral Abstract 632 in Session 614
Date and Time: Sunday, December 8, 4:30 - 6:00 PM
Presentation Time: 4:45 PM
Location: Marriott Marquis San Diego Marina, Grand Ballrooms 5-6
Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)
Presenter: Christopher J. Forlenza, MD (Memorial Sloan Kettering Cancer Center)
Poster Abstract 4427 in Session 624
Date and Time: Monday, December 9, 2024, 6:00 - 8:00 PM
Location: San Diego Convention Center, Halls G-H
Presenters are available for media interviews under the ASH Meeting Embargo Policy. To schedule an interview, send an email to Diane Dragaud, Director of Communications, at communications@ecog-acrin.org.
About ECOG-ACRIN
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) is a membership-based scientific organization known for advancing precision medicine and biomarker research through its leadership of major national clinical trials that integrate cutting-edge genomic approaches. Nearly 21,000 member researchers and advocates from approximately 1,400 cancer centers and community hospitals collaborate across ECOG-ACRIN’s nearly 40 scientific committees to design studies spanning the cancer care spectrum, from early detection to management of advanced disease. ECOG-ACRIN is funded primarily by the National Cancer Institute (NCI), part of the National Institutes of Health, through the National Clinical Trials Network (NCTN) and NCI Community Oncology Research Program (NCORP). To learn more, visit www.ecog-acrin.org and follow us on X/Twitter @EAonc, Facebook, LinkedIn, YouTube, and Instagram.
About PrECOG
PrECOG, LLC is a cancer research organization that designs and conducts innovative oncology studies through industry partnerships and research networks. The central focus of PrECOG is to conduct trials that align with the overall scientific mission and research goals of ECOG-ACRIN. To learn more, visit www.precogllc.org and follow us on X/Twitter @PrECOGonc, Facebook, and LinkedIn.
END
ECOG-ACRIN and PrECOG announce multiple presentations at ASH 2024
2024-11-07
ELSE PRESS RELEASES FROM THIS DATE:
Off-the-shelf thermoelectric generators can upgrade CO2 into chemicals. The combination could help us colonize Mars
2024-11-07
Readily available thermoelectric generators operating under modest temperature differences can power CO2 conversion, according to a proof-of-concept study by chemists at the University of British Columbia (UBC).
The findings open up the intriguing possibility that the temperature differentials encountered in an array of environments—from a typical geothermal installation on Earth to the cold, desolate surface of Mars—could power the conversion of CO2 into a range of useful fuels and chemicals.
“The environment ...
What makes human culture unique?
2024-11-07
Why is human culture — the shared body of knowledge passed down across generations — so much more powerful than animal cultures?
“What’s special about our species?” is a question scientists have wrestled with for centuries, and now a scientist at Arizona State University has a new hypothesis that could change the way we perceive ourselves, and the world around us.
“Ten years ago it was basically accepted that it was the ability of human culture to accumulate and evolve that made us special, but new discoveries about animal behavior are challenging these ideas and forcing us to rethink what makes our cultures, ...
Researchers discover dozens of new genes associated with disc herniations
2024-11-07
Lumbar disc herniation is one of the most common structural changes in the lower back and the most common cause of radiating pain, or sciatica, in the leg.
Hereditary risk factors for disc herniations were investigated in a recently published international study led by a University of Oulu research group, utilising data from FinnGen, the Estonian Biobank, and the UK Biobank. The study analyzed the genetic and health data of 829,699 participants.
The study found 41 novel regions of the genome that modify the disease risk for disc herniations, in addition ...
Research shows caterpillar fungus can slow down growth of cancer cells
2024-11-07
New research into a chemical produced by a caterpillar fungus that has shown promise as a possible cancer treatment has revealed how it interacts with genes to interrupt cell growth signals. The discovery is an important step towards developing new drugs for the treatment of the disease.
The research into a chemical produced by a caterpillar fungus has revealed how it may work as a cancer treatment. It interrupts the cell growth signals that are overactive in cancer, an approach that could be less damaging to healthy ...
Tanning bed access and usage is driving higher rates of melanoma in specific regions
2024-11-07
Philadelphia, November 7, 2024 – Melanoma accounts for only 1% of skin cancers in the United States but results in the largest number of skin cancer deaths. Investigators evaluated the potential link between the availability and use of tanning beds and the rising rates of melanoma in New England. They found compelling evidence linking tanning bed usage to increased melanoma risk. Their spatial epidemiologic study in the Journal of Investigative Dermatology, published by Elsevier, provides critical insights to inform public health strategies and reduce melanoma incidence.
The incidence of melanoma in the US has been increasing ...
Mitochondrial dysfunction research transforms mental health: Dr. Ana Andreazza's vision
2024-11-07
Toronto, Canada, 7 November 2024 – From a curious young scientist investigating her grandfather's family wine to a leading expert in mitochondrial health and mental illness, Dr. Ana Cristina Andreazza's journey exemplifies the power of personal motivation in driving scientific innovation. As founder and Scientific Director of the Mitochondrial Innovation Initiative (Mito2i), Dr. Andreazza is revolutionizing our understanding of the connection between cellular energy production and mental health.
In an illuminating Genomic Press Interview, published in Brain Medicine on November 7, 2024, ...
Dr. Nora Volkow shares insights on addiction science and harm reduction in Genomic Press interview
2024-11-07
Bethesda, Maryland, USA, 7 November 2024 – Dr. Nora Volkow's mission to revolutionize addiction treatment began with a deeply personal observation: watching how excessive substance use could profoundly alter a person’s behavior while simultaneously triggering social rejection by others. As the first woman and Hispanic Director of the National Institutes of Health’s National Institute on Drug Abuse (NIDA), Dr. Volkow has dedicated her career to investigating how drugs affect the human brain and how these disruptions contribute to the behavioral/emotional ...
25-year study reveals key factors in healthy brain aging and cognitive performance
2024-11-07
Edinburgh, Scotland, 7 November 2024 – A groundbreaking 25-year research program has unveiled key insights into how our brains age and what factors influence cognitive performance throughout life. The findings, published on 7 November 2024 in Genomic Psychiatry, draw from the Lothian Birth Cohorts (LBC) studies, which uniquely tracked participants' cognitive abilities from childhood through their eighth decade of life.
Professor Ian Deary and Dr. Simon Cox from the University of Edinburgh present remarkable discoveries that challenge conventional wisdom about brain aging. Their research ...
First clinical trial reveals promise of psilocybin treatment for anorexia nervosa
2024-11-07
San Diego, California, 7 November 2024 – In a groundbreaking exploration of psychedelic medicine's potential for treating one of psychiatry's most challenging conditions, researchers at University of California, San Diego (UCSD) provided an analysis and further details of a trial published in Nature Medicine (https://pmc.ncbi.nlm.nih.gov/articles/PMC10427429/) that had shown how psilocybin therapy affects individuals with anorexia nervosa. In the new peer-reviewed Emerging Topic article in Psychedelics ...
Fabrication of 4-inch wafer-scale heterostructure via PECVD drives AI semiconductor performance innovation!
2024-11-07
As artificial intelligence (AI) technology advances, the demand for higher-performing semiconductors is rapidly growing. The development of new materials and innovative structures to achieve high-performance semiconductors has become crucial. For the first time globally, a 4-inch heterostructure fabrication technology using plasma-enhanced chemical vapor deposition (PECVD) has been developed. This breakthrough enables the production of low-power, high-performance semiconductors, surpassing the capabilities of traditional silicon-based technology.
The research team led by Senior Researcher Hyeong-U Kim of the Semiconductor Manufacturing Research Center of the ...